Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators will study which patients respond meaningfully to therapy using pathophysiological traits measured at baseline sleep studies.
Obstructive Sleep Apnea
Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators will study which patients respond meaningfully to therapy using pathophysiological traits measured at baseline sleep studies.
Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy
-
Brigham and Women's Hospital, Boston, Massachusetts, United States, 02141
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
21 Years to 70 Years
ALL
No
Brigham and Women's Hospital,
Scott A Sands, PhD, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital
2024-12